AI assistant
NOXOPHARM LIMITED — AGM Information 2016
Oct 23, 2016
65437_rns_2016-10-23_3aedecb8-9977-4c99-8356-9044f45f3df9.pdf
AGM Information
Open in viewerOpens in your device viewer
==> picture [180 x 76] intentionally omitted <==
ASX: NOX
Noxopharm Limited
NOTICE OF MEETING NOXOPHARM 2016 AGM Sydney Briefing
November 25, 2016 at 4pm
ABN 50 608 966 123
Registered Office: Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia
Following the Company’s AGM in Melbourne on November 23, 2016, Noxopharm Limited ( ASX: NOX) will be holding an AGM Sydney Briefing on November 25[th] at 4pm at the Grace Hotel, 77 York Street, Sydney.
Attendees will have the opportunity to meet with the Noxopharm Board of Directors.
Board of Directors
Mr Peter Marks Chairman Non-Executive Director
Dr Graham Kelly Chief Executive Officer Managing Director
Dr Ian Dixon Non-Executive Director
CEO, Dr Graham Kelly, also will review the Company’s clinical trial programme and general drug development strategy.
Please RSVP for this event to: Prue Kelly [email protected] or call Noxopharm + 61 2 91442223
About Noxopharm
Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.